{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T09:32:47Z","timestamp":1795080767736,"version":"4.10.2"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.lanepe.2026.101623","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T09:51:59Z","timestamp":1771581119000},"page":"101623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Real-world evidence on RSV vaccine uptake, effectiveness, and safety in older adults: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"64","author":[{"given":"Daira","family":"Trusinska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0657-5664","authenticated-orcid":false,"given":"Sohail","family":"Ferdous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6647-4618","authenticated-orcid":false,"given":"Louise","family":"Lansbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1237-1405","authenticated-orcid":false,"given":"Cedric","family":"Burden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Stowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mensah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WeiShen","family":"LIM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5541-1535","authenticated-orcid":false,"given":"Cheryl","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4101-4535","authenticated-orcid":false,"given":"Ting","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"32","key":"10.1016\/j.lanepe.2026.101623_bib1","doi-asserted-by":"crossref","first-page":"696","DOI":"10.15585\/mmwr.mm7332e1","article-title":"Use of respiratory syncytial virus vaccines in adults aged >\/=60 years: updated recommendations of the advisory committee on immunization practices\u2013United States, 2024","volume":"73","author":"Britton","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101623_bib2","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1093\/cid\/ciaa730","article-title":"Respiratory syncytial virus-associated hospitalizations among adults with chronic medical conditions","volume":"73","author":"Prasad","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"166","key":"10.1016\/j.lanepe.2026.101623_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0105-2022","article-title":"Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries","volume":"31","author":"Nguyen-Van-Tam","year":"2022","journal-title":"Eur Respir Rev"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101623_bib4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/QCO.0000000000001000","article-title":"The disease burden of respiratory syncytial virus in older adults","volume":"37","author":"Kenmoe","year":"2024","journal-title":"Curr Opin Infect Dis"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101623_bib5","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/irv.12928","article-title":"Occurrence and disease burden of respiratory syncytial virus and other respiratory pathogens in adults aged >\/=65 years in community: a prospective cohort study in Japan","volume":"16","author":"Kurai","year":"2022","journal-title":"Influenza Other Respir Viruses"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101623_bib6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/irv.12723","article-title":"Epidemiology, clinical features, and resource utilization associated with respiratory syncytial virus in the community and hospital","volume":"14","author":"Smithgall","year":"2020","journal-title":"Influenza Other Respir Viruses"},{"issue":"Suppl 1","key":"10.1016\/j.lanepe.2026.101623_bib7","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1093\/infdis\/jiab600","article-title":"Performance assessment of a rapid molecular respiratory syncytial virus point-of-care test: a prospective community study in older adults","volume":"226","author":"Zuurbier","year":"2022","journal-title":"J Infect Dis"},{"issue":"26","key":"10.1016\/j.lanepe.2026.101623_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126323","article-title":"Annual public health and economic burden of medically attended respiratory syncytial virus illnesses among US adults","volume":"42","author":"Averin","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.lanepe.2026.101623_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.puhe.2024.08.004","article-title":"Quantifying the prevalence and determinants of respiratory syncytial virus (RSV) vaccine hesitancy in US adults aged 60 or older","volume":"238","author":"Motta","year":"2025","journal-title":"Public Health"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101623_bib10","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/irv.13043","article-title":"Change in functional status associated with respiratory syncytial virus infection in hospitalized older adults","volume":"16","author":"Branche","year":"2022","journal-title":"Influenza Other Respir Viruses"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101623_bib11","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1177\/00333549211041545","article-title":"Severe clinical outcomes among adults hospitalized with respiratory syncytial virus infections, New York City, 2017-2019","volume":"137","author":"Goldman","year":"2022","journal-title":"Public Health Rep"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101623_bib12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/irv.12910","article-title":"Estimating the burden of adult hospital admissions due to RSV and other respiratory pathogens in England","volume":"16","author":"Sharp","year":"2022","journal-title":"Influenza Other Respir Viruses"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101623_bib13","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/cid\/ciab595","article-title":"Incidence of respiratory syncytial virus infection among hospitalized adults, 2017-2020","volume":"74","author":"Branche","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.lanepe.2026.101623_bib14","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/infdis\/jiaa361","article-title":"Severe morbidity and Short- and Mid- to long-term mortality in older adults hospitalized with respiratory syncytial virus infection","volume":"222","author":"Tseng","year":"2020","journal-title":"J Infect Dis"},{"issue":"14","key":"10.1016\/j.lanepe.2026.101623_bib15","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.jacc.2018.02.013","article-title":"Respiratory syncytial virus and associations with cardiovascular disease in adults","volume":"71","author":"Ivey","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lanepe.2026.101623_bib16","series-title":"AREXVY","year":"2025"},{"key":"10.1016\/j.lanepe.2026.101623_bib17","series-title":"ABRYSVO","year":"2025"},{"key":"10.1016\/j.lanepe.2026.101623_bib18","series-title":"mResvia","year":"2024"},{"key":"10.1016\/j.lanepe.2026.101623_bib19","series-title":"Respiratory Syncytial Virus Infection (RSV)\u2013Vaccines for Adults","year":"2025"},{"key":"10.1016\/j.lanepe.2026.101623_bib20","series-title":"Your guide to the RSV vaccine for older adults","year":"2025"},{"key":"10.1016\/j.lanepe.2026.101623_bib21","series-title":"Respiratory Syncytial Virus (RSV) Immunisation: eligible groups","year":"2025"},{"key":"10.1016\/j.lanepe.2026.101623_bib22","series-title":"Respiratory Syncytial Virus (RSV): frequently asked questions","year":"2025"},{"issue":"16","key":"10.1016\/j.lanepe.2026.101623_bib23","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults","volume":"388","author":"Walsh","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.lanepe.2026.101623_bib24","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory syncytial virus prefusion F protein vaccine in older adults","volume":"388","author":"Papi","year":"2023","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.lanepe.2026.101623_bib25","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults","volume":"389","author":"Wilson","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101623_bib26","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/cid\/ciad658","article-title":"Cost-effectiveness of prefusion F protein-based vaccines against respiratory syncytial virus disease for older adults in the United States","volume":"78","author":"Moghadas","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101623_bib27","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s40121-024-00939-w","article-title":"Public health impact of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among older adults in the United States","volume":"13","author":"Molnar","year":"2024","journal-title":"Infect Dis Ther"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101623_bib28","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.ajt.2023.09.003","article-title":"Use of respiratory syncytial virus vaccines in older adults: recommendations of the advisory committee on immunization practices\u2013United States, 2023","volume":"23","author":"Melgar","year":"2023","journal-title":"Am J Transplant"},{"key":"10.1016\/j.lanepe.2026.101623_bib29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS peer review of electronic search strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.lanepe.2026.101623_bib31","series-title":"Critical Appraisal Tools for Use in JBI Systematic Reviews","year":"2020"},{"key":"10.1016\/j.lanepe.2026.101623_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103281","article-title":"Real-world uptake of nirsevimab, RSV maternal vaccine, and RSV vaccines for older adults: a systematic review and meta-analysis","volume":"84","author":"Trusinska","year":"2025","journal-title":"eClinicalMedicine"},{"issue":"11","key":"10.1016\/j.lanepe.2026.101623_bib33","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/thorax-2025-223376","article-title":"Real-world effectiveness and safety of nirsevimab, RSV maternal vaccine and RSV vaccines for older adults: a living systematic review and meta-analysis","volume":"80","author":"Lee","year":"2025","journal-title":"Thorax"},{"issue":"7109","key":"10.1016\/j.lanepe.2026.101623_bib34","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.lanepe.2026.101623_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.lanepe.2026.101623_bib36","article-title":"Atrial fibrillation after RSV vaccination among older adults [Epub ahead of print]","author":"Birabaharan","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101623_bib37","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.8322","article-title":"Effectiveness and safety of respiratory syncytial virus vaccine for US adults aged 60 years or older","volume":"8","author":"Fry","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.lanepe.2026.101623_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1427550","article-title":"Respiratory syncytial virus vaccination among US adults aged >\/=60 years","volume":"15","author":"Geng","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.lanepe.2026.101623_bib39","article-title":"Respiratory syncytial virus (RSV) vaccine effectiveness and antibody correlates of protection among older adults in the Community Vaccine Effectiveness (CoVE) observational study","author":"Godonou","year":"2025","journal-title":"medRxiv"},{"issue":"11","key":"10.1016\/j.lanepe.2026.101623_bib40","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf434","article-title":"Low uptake and disparities in respiratory syncytial virus vaccination among US veterans","volume":"12","author":"Kim","year":"2025","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101623_bib41","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2535755","article-title":"RSV vaccination uptake among adults aged 60 years and older in the United States during the 2023-2025 vaccination seasons","volume":"21","author":"La","year":"2025","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101623_bib42","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1111\/jgs.19610","article-title":"Disparities in respiratory syncytial virus vaccine uptake in the medicare fee-for-service population during 2023-2024 season","volume":"73","author":"Murphy","year":"2025","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.lanepe.2026.101623_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127033","article-title":"Respiratory syncytial virus vaccine uptake among adults aged >\/=60 years in a large, integrated healthcare system in Southern California 2023-2024","volume":"53","author":"Patrick","year":"2025","journal-title":"Vaccine"},{"issue":"10462","key":"10.1016\/j.lanepe.2026.101623_bib44","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(24)01738-0","article-title":"Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis","volume":"404","author":"Payne","year":"2024","journal-title":"Lancet"},{"issue":"51","key":"10.1016\/j.lanepe.2026.101623_bib45","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.15585\/mmwr.mm7251a3","article-title":"Coverage with influenza, respiratory syncytial virus, and updated COVID-19 vaccines among nursing home residents\u2013National Healthcare Safety Network, United States, December 2023","volume":"72","author":"Reses","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"46","key":"10.1016\/j.lanepe.2026.101623_bib46","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.15585\/mmwr.mm7346a2","article-title":"Coverage with influenza, respiratory syncytial virus, and COVID-19 vaccines among nursing home residents\u2013National Healthcare Safety Network, United States, November 2024","volume":"73","author":"Reses","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.lanepe.2026.101623_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127535","article-title":"Sociodemographic disparities in COVID-19 and RSV vaccine uptake among California adults >\/=60 years old who received influenza vaccination","volume":"62","author":"Rizzo","year":"2025","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.lanepe.2026.101623_bib48","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jama.2024.15775","article-title":"RSV vaccine effectiveness against hospitalization among US adults 60 years and older","volume":"332","author":"Surie","year":"2024","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.lanepe.2026.101623_bib49","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1001\/jama.2025.15896","article-title":"RSV vaccine effectiveness against hospitalization among US adults aged 60 years or older during 2 seasons","volume":"334","author":"Surie","year":"2025","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101623_bib50","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.2841","article-title":"Patient- and community-level characteristics associated with respiratory syncytial virus vaccination","volume":"8","author":"Surie","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.lanepe.2026.101623_bib51","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.50832","article-title":"Estimated vaccine effectiveness for respiratory syncytial virus-related lower respiratory tract disease","volume":"7","author":"Tartof","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.lanepe.2026.101623_bib52","article-title":"Estimated vaccine effectiveness for respiratory syncytial virus-related acute respiratory illness in older adults: findings from the first postlicensure season [Epub ahead of print]","author":"Tartof","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanepe.2026.101623_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127505","article-title":"RSV vaccine uptake among seniors: a path analysis approach","volume":"62","author":"Viskupic","year":"2025","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101623_bib54","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1473-3099(25)00064-7","article-title":"Early evidence of RSV vaccination impact on hospitalisation rates of older people in Scotland","volume":"25","author":"Hameed","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"10485","key":"10.1016\/j.lanepe.2026.101623_bib55","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S0140-6736(25)00346-0","article-title":"Early impact of RSV vaccination in older adults in England","volume":"405","author":"Mensah","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.lanepe.2026.101623_bib56","article-title":"Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospitalisation among adults aged 75-79 years in England [Epub ahead of print]","author":"Symes","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101623_bib57","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2550089","article-title":"A process evaluation of Ontario, Canada's 2023-24 older-adult RSV vaccination program","volume":"21","author":"Morrison","year":"2025","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101623_bib58","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1473-3099(24)00796-5","article-title":"Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study","volume":"25","author":"Bajema","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"21","key":"10.1016\/j.lanepe.2026.101623_bib59","doi-asserted-by":"crossref","first-page":"489","DOI":"10.15585\/mmwr.mm7321a3","article-title":"Early safety findings among persons aged >\/=60 years who received a respiratory syncytial virus vaccine\u2013United States, May 3, 2023-April 14, 2024","volume":"73","author":"Hause","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.lanepe.2026.101623_bib60","article-title":"Post-licensure safety of respiratory syncytial virus vaccines, Vaccine Adverse Event Reporting System, United States, May 2023-December 2024","volume":"56","author":"Li","year":"2025","journal-title":"Prev Med Rep"},{"key":"10.1016\/j.lanepe.2026.101623_bib61","article-title":"Evaluation of Guillain-Barr\u00e9 syndrome following respiratory syncytial virus vaccination among medicare beneficiaries 65 years and older","author":"Lloyd","year":"2025","journal-title":"medRxiv [Preprint]"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101623_bib62","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2550857","article-title":"Post-marketing safety monitoring of RSV vaccines: a real-world study based on the Vaccine Adverse Event Reporting System (VAERS)","volume":"21","author":"Bao","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.lanepe.2026.101623_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127873","article-title":"Near real-time surveillance and tree-based data mining to assess the safety of respiratory syncytial virus vaccines in older adults in the vaccine safety datalink","volume":"67","author":"Donahue","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.lanepe.2026.101623_bib64","article-title":"Safety and immunogenicity of adjuvanted respiratory syncytial virus vaccine in high-risk transplant recipients: an interventional cohort study [Epub ahead of print]","author":"Hall","year":"2025","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101623_bib65","article-title":"Characteristics of the first Italian older adults vaccinated with an adjuvanted respiratory syncytial virus (RSV) vaccine","volume":"61","author":"Domnich","year":"2025","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.lanepe.2026.101623_bib66","article-title":"Short term safety profile of respiratory syncytial virus vaccine in adults aged >\/= 60 years in Australia","volume":"56","author":"Nguyen","year":"2025","journal-title":"Lancet Reg Health West Pac"},{"issue":"7","key":"10.1016\/j.lanepe.2026.101623_bib67","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.ajt.2025.03.025","article-title":"Respiratory syncytial virus prefusion F3 vaccine in lung transplant recipients elicits CD4+ T cell response in all vaccinees","volume":"25","author":"Havlin","year":"2025","journal-title":"Am J Transplant"},{"issue":"16","key":"10.1016\/j.lanepe.2026.101623_bib68","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1001\/jama.2025.16744","article-title":"Respiratory syncytial virus vaccination in adult allogeneic hematopoietic cell transplant recipients","volume":"334","author":"Lotscher","year":"2025","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.lanepe.2026.101623_bib69","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.33828","article-title":"Respiratory syncytial virus vaccination in allogeneic hematopoietic stem cell transplant recipients","volume":"8","author":"Redjoul","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101623_bib70","article-title":"Neutralizing antibody response to the AreXvy respiratory syncytial virus vaccine in lung transplant recipients: assessment against reference and seasonal strains","volume":"13","author":"Levy","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.lanepe.2026.101623_bib71","series-title":"2023-24 RSV Vaccination Coverage, Adults 65 Years and Older","year":"2024"},{"issue":"8","key":"10.1016\/j.lanepe.2026.101623_bib72","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1007\/s11606-020-06456-z","article-title":"Shared clinical decision-making recommendations for adult immunization: what do physicians think?","volume":"36","author":"Kempe","year":"2021","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.lanepe.2026.101623_bib73","series-title":"RSV Vaccine Coverage Report in Older Adults for Catch-up Cohorts in England: June 2025","year":"2025"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101623_bib74","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1089\/heq.2021.0177","article-title":"Racial and ethnic disparities in adult vaccination: a review of the state of evidence","volume":"6","author":"Granade","year":"2022","journal-title":"Health Equity"},{"key":"10.1016\/j.lanepe.2026.101623_bib75","series-title":"Flu Vaccination Coverage, United States, 2023\u201324 Influenza Season 2024","year":"2024"},{"issue":"175","key":"10.1016\/j.lanepe.2026.101623_bib76","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0222-2024","article-title":"Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024","volume":"34","author":"Zhou","year":"2025","journal-title":"Eur Respir Rev"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101623_bib77","first-page":"1074","article-title":"Noninferior immunogenicity and consistent safety of respiratory syncytial virus prefusion F protein vaccine in adults 50-59 years compared to >\/=60 years of age","volume":"79","author":"Ferguson","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101623_bib78","article-title":"Vaccination recommendations in solid organ transplant adult candidates and recipients","volume":"11","author":"Vigano","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101623_bib79","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"issue":"12","key":"10.1016\/j.lanepe.2026.101623_bib80","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1001\/jamainternmed.2021.6227","article-title":"Risk of Guillain-Barre syndrome following recombinant zoster vaccine in medicare beneficiaries","volume":"181","author":"Goud","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101623_bib81","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/infdis\/jiaa543","article-title":"Guillain-Barre syndrome after high-dose influenza vaccine administration in the United States, 2018-2019 season","volume":"223","author":"Perez-Vilar","year":"2021","journal-title":"J Infect Dis"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226000359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226000359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:35:11Z","timestamp":1777883711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776226000359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":80,"alternative-id":["S2666776226000359"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101623","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world evidence on RSV vaccine uptake, effectiveness, and safety in older adults: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101623","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101623"}}